Activation of Brown Adipose Tissue Metabolism Using Mirabegron
NCT ID: NCT04823442
Last Updated: 2024-12-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
9 participants
INTERVENTIONAL
2021-01-21
2022-04-04
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Together, several results establish a previously unappreciated cross-talk between Gs-coupled ADRB1 and ADRB3 in adipose tissue for the control of glucose homeostasis. Moreover, these data suggest that antagonizing ADRB1 may be a good way to significantly lower the dose of ADRB3 agonist required for glucose control.
Therefore, we believe that there are therapeutic opportunities in targeting adrenergic receptors for the treatment of T2D at least in young/middle aged people.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The radioactive PET tracers (PET: positron emission tomography) used in this study are the \[11C\]-acetate and \[18F\]-FDG to estimate BAT oxidative metabolism and glucose metabolism, respectively. The perfusion of \[6,6 D2\]-glucose, \[1,1,2,3,3-2H\]-glycerol and \[U-13C\]-palmitate stable isotopes will also be performed in this study from time -150 min. to +300 min to examine the systemic appearance rate of glucose, glycerol and fatty acids, respectively. These studies will be almost identical (same perfusion of stable and radioactive tracers, same number of PET acquisitions) except for the drug which will be administered orally at time 0.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
BASIC_SCIENCE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Study A
Metabolic PET study with mirabegron
Mirabegron
Mirabegron: a single dose of 200 mg mirabegron (4 tablets of 50 mg)
Study B
Metabolic PET study with mirabegron and bisoprolol
Mirabegron
Mirabegron: a single dose of 200 mg mirabegron (4 tablets of 50 mg)
Bisoprolol Fumarate
a single dose of 10 mg (2 tablets of 5 mg)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Mirabegron
Mirabegron: a single dose of 200 mg mirabegron (4 tablets of 50 mg)
Bisoprolol Fumarate
a single dose of 10 mg (2 tablets of 5 mg)
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* BMI ≤ 30 kg/m2.
Exclusion Criteria
* More than 2 alcohol consumption per day;
* More than 1 cigarette per day;
* History of total cholesterol level \> 7 mmol/L, of cardiovascular disease, hypertensive crisis;
* Treatment with fibrates, thiazolidinedione, insulin,betablockers or other drugs with effects on insulin resistance or lipid metabolism (exception for antihypertensive drugs, statins or metformin);
* Presence of a noncontrolled thyroid disease, renal or hepatic disease, history of pancreatitis, bleeding diatheses, cardiovascular disease or any other serious medical conditions;
* History of serious gastrointestinal disorders (malabsorption, peptic ulcer, gastroesophageal reflux having required a surgery, etc.); reflux having required a surgery, etc.);
* Presence of a pacemaker;
* Have undergone of PET study or CT scan in the past year;
* Chronic administration of any medication;
18 Years
35 Years
MALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Laval University
OTHER
Université de Sherbrooke
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Denis Blondin
Assisant professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Denis Blondin
Role: PRINCIPAL_INVESTIGATOR
Université de Sherbrooke
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Centre de recherche du CHUS
Sherbrooke, Quebec, Canada
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Dumont L, Caron A, Richard G, Croteau E, Fortin M, Frisch F, Phoenix S, Dubreuil S, Guerin B, Turcotte EE, Carpentier AC, Blondin DP. The effects of the beta1-adrenergic receptor antagonist bisoprolol administration on mirabegron-stimulated human brown adipose tissue thermogenesis. Acta Physiol (Oxf). 2024 May;240(5):e14127. doi: 10.1111/apha.14127. Epub 2024 Mar 19.
Related Links
Access external resources that provide additional context or updates about the study.
publication of results
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2021-3791
Identifier Type: -
Identifier Source: org_study_id